A high throughput electrochemiluminescence assay for the quantification of frataxin protein levels.

Steinkellner, H., Scheiber-Mojdehkar, B., Goldenberg, H., Sturm, B.
Journal   Anal Chim Acta.
Analytes Measured  
Matrix Tested   Human lymphoblast cell lysates, human fibroblast cell lysates, HeLa cell lysates, mouse liver cell lysates, mouse brain lysates
Year   2009
Volume   659
Page Numbers   129-32
Application   Alzheimers
Friedreich's ataxia (FRDA) is an autosomal recessive neurodegenerative disease affecting 1 in 50,000 people and is caused by a GAA-trinucleotide expansion in the frataxin gene located on chromosome locus 9q13 which results in a markedly reduced expression of frataxin, a small mitochondrial protein. The exact function of frataxin is still unknown and currently there is no approved treatment available. In the near future there will be a high demand for measuring frataxin protein levels due to the development of therapeutic strategies for FRDA based on manipulating frataxin expression levels in vivo. In this paper we describe the development of an electrochemiluminescence assay (ECLIA) to measure frataxin protein levels in a 96-well plate format. The ECLIA for frataxin is able to measure human and mouse samples and is highly quantitative, accurate and reproducible, with low intra- and inter-assay error throughout a wide working range. The assay has an excellent precision and provides a new tool for the set up of high-throughput screening for basic research and for clinical studies with FRDA patients.

View Publications
Browse Our Products

By Analytes
By Applications
Customer Service/Orders

Scientific/Technical Support

Instrument Support

Company Headquarters